The aim of this independent study was to investigate differences in efficacy between oxerutins (Venoruton) and 500 mg micronized diosmin + hesperidin (D+H) (Daflon) in patients with chronic venous insufficiency (CVI), evaluating venous-related quality of life (Ve-QOL). A first group of 90 patients with severe venous hypertension (CVI, ankle swelling) was randomized to treatment with oxerutins or D+H. The oxerutins group received oral oxerutins (2 g/day); the D+H group received 3 (500 mg) tablets daily every 8 hours for 8 weeks. A second group of 122 comparable patients was included in a registry following the same study format. The 2 treatments were administered with the same methods and procedures. Clinical conditions were comparable. All patients completing 8 weeks of treatment were included in a registry. Specialists or general practitioners included patients when they considered that clinical conditions were compatible with treatment indications using 1 of the 2 treatments on the basis of their evaluation and experience. When cases were compatible with the registry, the prescribing physician communicated the case to our monitoring center. Patients were evaluated without interfering with their treatment. The main target of evaluation for this study was the change in Ve-QOL (range, 0-100) induced by treatment. A specific Ve-QOL questionnaire was used for this study. Ve-QOL score is a specific expression of the changes in QOL induced by CVI in patients between 35 and 75 years old (defined in our population studies) in which no other significant clinical disease is present (as a confounding factor affecting QOL). Two hundred twelve patients completed the 2 parts of the study. The 2 treatment groups were comparable for age and gender distribution. The mean age was 42 years (SD ±5.5) in the oxerutins group and 41.5 (SD ±6) in the D+H group. There were no differences in the severity of CVI between the treatment groups at inclusion. A significant decrease (46.8%, p<0.05) in Ve-QOL score; that is, improvement, was observed in the oxerutins group. The change in Ve-QOL was significantly less in the D+H group (15.5%). In conclusion, CVI, venous microangiopathy, and edema were significantly improved by the treatment with oxerutins; the improvement in QOL was significantly greater in the oxerutins group. The comparison with D+H indicates that oxerutins is comparatively more effective on Ve-QOL and on signs/symptoms of CVI
- Family Elder
- Posts: 683
- Joined: Mon Sep 04, 2006 2:00 pm
- Location: LeftCoast Canada
From Novartis site
Hayes inspired Calcitriol+D3 2013-2014
Coimbra Protocol 2014-16
DrG B12 Transdermal Spray 2014-16
Low-Dose Immunotherapy 2015-16
My Current Regimen http://www.thisisms.com/forum/regimens-f22/topic25634.html
It is sold over the counter, so I will give it a go. I did a search for any studies in relation to MS, and the only one that keeps coming up was this one, which did not find anything.
"A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis. Mult Scler 2005;11(2):166-168"
http://www.direct-ms.org/pdf/NutritionM ... 0trial.pdf
However, this study only appeared to use what appears to be very small doses.
The tablets I have are 500mg, and the starting dose is 2 a day, and I have read on the web that some suggest a lot more. The leaflet indicates a change should occur after about 10 days.One HE tablet contained 90 mg bromelain, 48 mg trypsin and 100 mg rutosid
http://www.systemicenzymesupport.org/co ... erosis.htm
and there is a lot more in it.After adjusting the baseline values of either group to 100%, a statistically significant difference in favor of the enzymes was demonstrated from the sixth month (p < .01 ), an even highly significant difference at end of therapy (p < .001 ).
If the difference at baseline is judged as clinically so relevant that a direct comparison during the course of the therapy is not acceptable, there is nevertheless a difference in favor of the enzymes in the change of the Kurtzke scale: whereas the value improved until the last available vaIue in the enzyme group by 24.2% (from 3.3 to 2.5), it worsened in the corticosteroid group by (-)2.2% from 4.5 to 4.6.
- Similar Topics
- Last post